Eclipse buy gives Bionomics cancer stem cell foothold
This article was originally published in Scrip
Executive Summary
The Australian drug development firm Bionomics is spending Aus$10 million ($10.5 million) to acquire a private US venture that will give it both candidate antibody therapeutics against cancer stem cells (CSCs) and a direct presence in the US.
You may also be interested in...
New Company, Big Goal: Serial Entrepreneur Jonathan Lim Launches Erasca To 'Erase Cancer'
Lim, CEO of Ignyta when it was sold to Roche earlier this year, has moved on to the start-up Erasca with $42m in Series A venture cash to develop "precision oncology" drugs.
Hit And Miss First Half For Takeda
While it has raised the full-year profit outlook, Takeda came in under analysts' consensus for some of its fiscal first-half figures, pointing to a growing forex impact.
Bumpy Japan Zolgensma Review Holds Lessons For Applicants
Product review report reveals multiple delays and missteps on route to market, holding valuable lessons for other gene therapy developers but also evidencing an ultimately welcoming environment.
Need a specific report? 1000+ reports available
Buy Reports